Literature DB >> 14751566

Histamine participates in the early phase of trabecular bone loss in ovariectomized rats.

Ph Lesclous1, D Guez, B Baroukh, A Vignery, J L Saffar.   

Abstract

We have previously reported that cimetidine, a reference H2 receptor antagonist, attenuates the initial osteoclastic burst and subsequent trabecular bone loss induced by ovariectomy (ovx) in rats. This study was designed to determine whether these effects are specific to H2 antagonism. To this end, we compared the effects of two H2 receptor antagonists, cimetidine and famotidine. In addition, we analyzed the response of histamine-producing cells to these inhibitors. Seventy-two 90-day-old female Sprague-Dawley rats were ovariectomized or sham-operated, and received single daily intramuscular injections of cimetidine (125 mg/kg), famotidine (10 mg/kg), or vehicle. The animals were killed 14 days after surgery and their femurs were processed for histomorphometry. Trabecular bone volume was reduced by 30% in ovx rats and by 15% in cimetidine- and famotidine-treated rats. Architectural parameters were reduced by about 20% in ovx rats. Cimetidine and famotidine attenuated these consequences of ovx by about 50%. Trabecular connectivity was deteriorated by ovx, while cimetidine and famotidine attenuated this effect. Resorption parameters were increased by ovx, while cimetidine and famotidine prevented this increase. Kinetic bone formation parameters were increased by ovx, while cimetidine and famotidine had no influence. Neither cimetidine nor famotidine had any observable effect in sham-treated rats. Mast cell numbers increased by 250% in ovx rats and by only 40% in H2 antagonists-treated ovx rats. A resident histamine-positive, non-mast cell, population found in bone marrow was increased by 25% by ovx. Interestingly, cimetidine and famotidine reduced this population in both sham-operated and ovx rats, famotidine being more potent than cimetidine. These results show that H(2) receptor blockade partially prevents the consequences of castration on cancellous bone resorption in female rats, and strongly suggest that histamine participates in the mediator network regulating estrogen deficiency induced bone resorption. A large population of histamine-producing cells, which differ morphologically from mast cells and belong to an immature marrow population, may be a source of histamine in this model. The H(2) blockers targeted this population, and this effect appeared to explain the anti-resorptive action of the two drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751566     DOI: 10.1016/j.bone.2003.08.007

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  14 in total

1.  Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.

Authors:  Chun-Sick Eom; Sang Min Park; Seung-Kwon Myung; Jae Moon Yun; Jeong-Soo Ahn
Journal:  Ann Fam Med       Date:  2011 May-Jun       Impact factor: 5.166

Review 2.  Risk of fracture and pneumonia from acid suppressive drugs.

Authors:  Chun-Sick Eom; Sang-Soo Lee
Journal:  World J Methodol       Date:  2011-09-26

3.  Systemic mastocytosis with skeletal involvement: a case report and review of the literature.

Authors:  Maurizio Benucci; Catia Bettazzi; Stefania Bracci; Plinio Fabiani; Laura Monsacchi; Carlo Cappelletti; Mariangela Manfredi; Stefania Ciolli
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

4.  Mast cells and MMP-9 in the lamina propria during eruption of rat molars: quantitative and immunohistochemical evaluation.

Authors:  Paulo Sérgio Cerri; Jorge Alonso Pereira-Júnior; Natalia Barrionuevo Biselli; Estela Sasso-Cerri
Journal:  J Anat       Date:  2010-06-16       Impact factor: 2.610

5.  Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts.

Authors:  Martin Biosse-Duplan; Brigitte Baroukh; Michel Dy; Marie-Christine de Vernejoul; Jean-Louis Saffar
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

Review 6.  [Pharmacogenic osteoporosis beyond cortisone. Proton pump inhibitors, glitazones and diuretics].

Authors:  P H Kann; P Hadji; R S Bergmann
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

7.  Mast Cell Mediators Inhibit Osteoblastic Differentiation and Extracellular Matrix Mineralization.

Authors:  William Marcatti Amarú Maximiano; Elaine Zayas Marcelino da Silva; Ana Carolina Santana; Paulo Tambasco de Oliveira; Maria Célia Jamur; Constance Oliver
Journal:  J Histochem Cytochem       Date:  2017-10-05       Impact factor: 2.479

8.  Antihistamine therapy and bone mineral density: analysis in a population-based US sample.

Authors:  Mitsuyo Kinjo; Soko Setoguchi; Daniel H Solomon
Journal:  Am J Med       Date:  2008-12       Impact factor: 4.965

9.  Increased apoptosis in osteoclasts and decreased RANKL immunoexpression in periodontium of cimetidine-treated rats.

Authors:  Renata Longhini; Priscila Aparecida de Oliveira; Ana Paula de Souza Faloni; Estela Sasso-Cerri; Paulo Sérgio Cerri
Journal:  J Anat       Date:  2012-12-02       Impact factor: 2.610

10.  Presence of mast cells and the expression of metalloproteinase 9 in the gingiva of ovariectomized rats with periodontal disease.

Authors:  Vanessa Ávila Sarmento Silveira; Renata Falchete do Prado; Yasmin Rodarte Carvalho; Horácio Faig-Leite
Journal:  J Oral Biol Craniofac Res       Date:  2017-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.